Cost-effectiveness of osteoporosis treatments in postmenopausal women using FRAX™ thresholds for decision - 26/01/13
, Francis Guillemin c, Christian Roux d
Corresponding author. Tel.: +33 6 80 57 14 28; fax: +33 1 49 81 36 74/97.Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 6 |
| Iconographies | 3 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Purpose |
FRAX™ is a fracture prediction algorithm to determine a patient’s absolute fracture risk. There is a growing consensus that osteoporosis treatment should be based on individual 10-year fracture probability, as calculated in the FRAX™ algorithm, rather than on T-scores alone.
Objective |
Our objective was to evaluate the cost-effectiveness of five years of branded alendronate therapy in postmenopausal French women with a known FRAX™ score.
Method |
A Markov cohort state transition model using FRAX™ values and whenever possible population-specific data and probabilities. We estimated the incremental cost-effectiveness ratio (ICER) of alendronate versus no treatment in postmenopausal women with FRAX™ ranging from 10 to 3%.
Outcomes |
Number of women to treat (NNT) for preventing hip fracture, costs, quality-adjusted life-years, incremental cost-effectiveness ratios.
Results |
The incremental cost-effectiveness ratios (ICER) compared to no treatment at age 70 ranged from €104,183 to €413,473 per QALY when FRAX™ decreased from 10 to 3%. The NNTs for preventing one hip fracture ranged from 97 to 388 according to age (50–80 years) and FRAX™. Sensitivity analyses showed that the main determinants of cost-effectiveness were adherence to therapy and cost of treatment.
Conclusion |
Using French costs of branded drug and current estimates of treatment efficacy, alendronate therapy for 70-year-old women with 10-year probability of hip fracture of 10% just meets the accepted cost-effectiveness threshold. Improving treatment adherence and/or decreasing treatment cost lowers the ICER. The model however underestimates the potential benefit by excluding other fractures.
Le texte complet de cet article est disponible en PDF.Keywords : Cost-effectiveness, Osteoporosis, Hip fracture, Alendronate, FRAX™
Plan
Vol 80 - N° 1
P. 64-69 - janvier 2013 Retour au numéro
Article précédent
- Bone health during late adolescence: Effects of an 8-month training program on bone geometry in female athletes
- Béatrice Ferry, Eric Lespessailles, Pierre Rochcongar, Martine Duclos, Daniel Courteix
- Impairment of two types of circulating endothelial progenitor cells in patients with glucocorticoid-induced avascular osteonecrosis of the femoral head
- Chao Chen, Shuhua Yang, Yong Feng, Xinghuo Wu, Dong Chen, Qian Yu, Xiaohong Wang, Jing Li, Juan Chen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?